

Christopher E Kvistad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6411839/publications.pdf>

Version: 2024-02-01

42
papers

1,060
citations

567281

15
h-index

434195

31
g-index

43
all docs

43
docs citations

43
times ranked

1434
citing authors

#	ARTICLE	IF	CITATIONS
1	Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2), Tj ETQq1 1 The, 2022, 21, 511-519.	0.784314 10.2	rgBT /Over 88
2	Tenecteplase versus alteplase after acute ischemic stroke at high age. <i>International Journal of Stroke</i> , 2021, 16, 295-299.	5.9	11
3	Clinical manifestation of acute cerebral infarcts in multiple arterial territories. <i>Brain and Behavior</i> , 2021, 11, e2296.	2.2	3
4	The Course of Carotid Plaque Vulnerability Assessed by Advanced Neurosonology. <i>Frontiers in Neurology</i> , 2021, 12, 702657.	2.4	3
5	Sex Differences in the Norwegian Tenecteplase Trial (NOR-TEST). <i>European Journal of Neurology</i> , 2021, , .	3.3	2
6	Persistent Microembolic Signals in the Cerebral Circulation on Transcranial Doppler after Intravenous Sulfur Hexafluoride Microbubble Infusion. <i>Journal of Neuroimaging</i> , 2020, 30, 146-149.	2.0	6
7	Safety and predictors of stroke mimics in The Norwegian Tenecteplase Stroke Trial (NOR-TEST). <i>International Journal of Stroke</i> , 2019, 14, 508-516.	5.9	15
8	Incidence and Etiologies of Stroke Mimics After Incident Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2019, 50, 2937-2940.	2.0	10
9	Short-Term Outcome and In-Hospital Complications After Acute Cerebral Infarcts in Multiple Arterial Territories. <i>Stroke</i> , 2019, 50, 3625-3627.	2.0	10
10	Safety and Outcomes of Tenecteplase in Moderate and Severe Ischemic Stroke. <i>Stroke</i> , 2019, 50, 1279-1281.	2.0	29
11	U-shaped relationship between hemoglobin level and severity of ischemic stroke. <i>Acta Neurologica Scandinavica</i> , 2019, 140, 56-61.	2.1	8
12	Recurrent ischemic stroke: Incidence, predictors, and impact on mortality. <i>Acta Neurologica Scandinavica</i> , 2019, 140, 3-8.	2.1	94
13	Tenecteplase Versus Alteplase Between 3 and 4.5 Hours in Low National Institutes of Health Stroke Scale. <i>Stroke</i> , 2019, 50, 498-500.	2.0	15
14	High risk of early neurological worsening of lacunar infarction. <i>Acta Neurologica Scandinavica</i> , 2019, 139, 143-149.	2.1	3
15	When to Screen Ischaemic Stroke Patients for Cancer. <i>Cerebrovascular Diseases</i> , 2018, 45, 42-47.	1.7	47
16	Contrast-enhanced sonothrombolysis in acute ischemic stroke patients without intracranial large vessel occlusion. <i>Acta Neurologica Scandinavica</i> , 2018, 137, 256-261.	2.1	2
17	Clinical Importance of Temporal Bone Features for the Efficacy of Contrast-Enhanced Sonothrombolysis: a Retrospective Analysis of the NOR-SASS Trial. <i>Translational Stroke Research</i> , 2018, 9, 333-339.	4.2	1
18	A score for paroxysmal atrial fibrillation in acute ischemic stroke. <i>International Journal of Stroke</i> , 2018, 13, 496-502.	5.9	5

#	ARTICLE	IF	CITATIONS
19	Intravenous Thrombolysis in Ischemic Stroke Patients With Active Cancer. <i>Frontiers in Neurology</i> , 2018, 9, 811.	2.4	22
20	Thirty-day recurrence after ischemic stroke or TIA. <i>Brain and Behavior</i> , 2018, 8, e01108.	2.2	16
21	Elevated body temperature in ischemic stroke associated with neurological improvement. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 414-418.	2.1	6
22	NOR-SASS (Norwegian Sonothrombolysis in Acute Stroke Study). <i>Stroke</i> , 2017, 48, 335-341.	2.0	52
23	Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. <i>Lancet Neurology</i> , The, 2017, 16, 781-788.	10.2	305
24	A stress-related explanation to the increased blood pressure and its course following ischemic stroke. <i>Vascular Health and Risk Management</i> , 2016, Volume 12, 435-442.	2.3	11
25	Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities. <i>CNS Drugs</i> , 2016, 30, 101-108.	5.9	6
26	A Family History of Stroke Is Associated with Increased Intima-Media Thickness in Young Ischemic Stroke - The Norwegian Stroke in the Young Study (NOR-SYS). <i>PLoS ONE</i> , 2016, 11, e0159811.	2.5	5
27	Therapeutic Potential of Tenecteplase in the Management of Acute Ischemic Stroke. <i>CNS Drugs</i> , 2015, 29, 811-818.	5.9	31
28	A pragmatic approach to sonothrombolysis in acute ischaemic stroke: the Norwegian randomised controlled sonothrombolysis in acute stroke study (NOR-SASS). <i>BMC Neurology</i> , 2015, 15, 110.	1.8	15
29	Is higher body temperature beneficial in ischemic stroke patients with normal admission CT angiography of the cerebral arteries?. <i>Vascular Health and Risk Management</i> , 2014, 10, 49.	2.3	6
30	Body temperature and major neurological improvement in tPA-treated stroke patients. <i>Acta Neurologica Scandinavica</i> , 2014, 129, 325-329.	2.1	15
31	Diffusion-Weighted Lesions in Stroke Patients with Transient Symptoms - Where Are They Located?. <i>Cerebrovascular Diseases</i> , 2014, 38, 219-225.	1.7	7
32	Mild stroke: safety and outcome in patients receiving thrombolysis. <i>Acta Neurologica Scandinavica</i> , 2014, 129, 37-40.	2.1	33
33	Is smoking associated with favourable outcome in tPA-treated stroke patients?. <i>Acta Neurologica Scandinavica</i> , 2014, 130, 299-304.	2.1	21
34	A Dark Side of Subcortical Diffusion-Weighted Lesions?. <i>Stroke</i> , 2014, 45, 2710-2716.	2.0	2
35	Diffusion-weighted lesions in acute ischaemic stroke patients with migraine. <i>Acta Neurologica Scandinavica</i> , 2014, 129, 41-46.	2.1	15
36	The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke. <i>BMC Neurology</i> , 2014, 14, 106.	1.8	44

#	ARTICLE	IF	CITATIONS
37	Elevated Admission Blood Pressure and Stroke Severity in Acute Ischemic Stroke: The Bergen NORSTROKE Study. <i>Cerebrovascular Diseases</i> , 2013, 36, 351-354.	1.7	35
38	Does a History of Migraine Affect the Rate of Thrombolysis in Young Stroke Patients?. <i>Stroke Research and Treatment</i> , 2013, 2013, 1-5.	0.8	3
39	Safety of off-label stroke treatment with tissue plasminogen activator. <i>Acta Neurologica Scandinavica</i> , 2013, 128, 48-53.	2.1	29
40	Clinical implications of increased use of MRI in TIA. <i>Acta Neurologica Scandinavica</i> , 2013, 128, 32-38.	2.1	10
41	Persistent middle cerebral artery occlusion associated with lower body temperature on admission. <i>Vascular Health and Risk Management</i> , 2013, 9, 297.	2.3	3
42	Low body temperature associated with severe ischemic stroke within 6 hours of onset: The Bergen NORSTROKE Study. <i>Vascular Health and Risk Management</i> , 2012, 8, 333.	2.3	14